Artemisinin resistance or artemisinin-based combination therapy resistance?

The Lancet Infectious Diseases

Volumn 13, Issue 2, 2013, Pages 114-115

  Wongsrichanalai, Chansuda ^a  

^a not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE;

ANTIMALARIAL DRUG RESISTANCE; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; LETTER; MALARIA CONTROL; MORBIDITY; MORTALITY; NONHUMAN; PARASITE CLEARANCE; PARASITEMIA; PRIORITY JOURNAL;

EID: 84872537684     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70349-3     Document Type: Letter

References (5)

1. Breman JG Resistance to artemisinin-based combination therapy. Lancet Infect Dis 2012, 12:820-822.
2. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum malaria in Pursat province, western Cambodia: a parasite-clearance-rate study. Lancet Infect Dis 2012, 12:851-858.
3. Update on artemisinin resistance World Health Organization Global Malaria Programme, (accessed Oct 15, 2012). http://www.who.int/malaria/publications/atoz/arupdate042012.pdf.
4. The status of drug-resistant malaria along the ThailandûMyanmar border. Revised 9 May 2012 World Health Organization Global Malaria Programme, (accessed Oct 15, 2012). http://www.who.int/malaria/publications/atoz/drug_resistance_myanmar_thailand_border_may_2012.pdf.
5. Wongsrichanalai C, Thimasarn K, Sirichaisinthop J Antimalarial drug combination policy: a caveat. Lancet 2000, 355:2245-2247.